First trials test targeting of α-synuclein for Parkinson disease

Nat Rev Neurol. 2022 Dec;18(12):703-704. doi: 10.1038/s41582-022-00726-6.

Author

Lorraine V Kalia^{1

2

3}

Affiliations

¹ Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. lorraine.kalia@utoronto.ca.
² Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada. lorraine.kalia@utoronto.ca.
³ Krembil Research Institute, University Health Network, Toronto, Ontario, Canada. lorraine.kalia@utoronto.ca.

PMID: 36151474
DOI: 10.1038/s41582-022-00726-6

No abstract available

Publication types

Comment

MeSH terms

Humans
Parkinson Disease* / diagnosis
alpha-Synuclein*

Substances

alpha-Synuclein